These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

136 related articles for article (PubMed ID: 38960841)

  • 21. Intestinal function and transit associate with gut microbiota dysbiosis in cystic fibrosis.
    Marsh R; Gavillet H; Hanson L; Ng C; Mitchell-Whyte M; Major G; Smyth AR; Rivett D; van der Gast C
    J Cyst Fibros; 2022 May; 21(3):506-513. PubMed ID: 34895838
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Correctors (specific therapies for class II CFTR mutations) for cystic fibrosis.
    Southern KW; Patel S; Sinha IP; Nevitt SJ
    Cochrane Database Syst Rev; 2018 Aug; 8(8):CD010966. PubMed ID: 30070364
    [TBL] [Abstract][Full Text] [Related]  

  • 23. [Chinese experts consensus statement: diagnosis and treatment of cystic fibrosis (2023)].
    ; ;
    Zhonghua Jie He He Hu Xi Za Zhi; 2023 Apr; 46(4):352-372. PubMed ID: 36990700
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Alterations of mucosa-attached microbiome and epithelial cell numbers in the cystic fibrosis small intestine with implications for intestinal disease.
    Kelly J; Al-Rammahi M; Daly K; Flanagan PK; Urs A; Cohen MC; di Stefano G; Bijvelds MJC; Sheppard DN; de Jonge HR; Seidler UE; Shirazi-Beechey SP
    Sci Rep; 2022 Apr; 12(1):6593. PubMed ID: 35449374
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Impact of the CFTR-potentiator ivacaftor on airway microbiota in cystic fibrosis patients carrying a G551D mutation.
    Bernarde C; Keravec M; Mounier J; Gouriou S; Rault G; Férec C; Barbier G; Héry-Arnaud G
    PLoS One; 2015; 10(4):e0124124. PubMed ID: 25853698
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Individual and Group Response of Treatment with Ivacaftor on Airway and Gut Microbiota in People with CF and a S1251N Mutation.
    Kristensen MI; de Winter-de Groot KM; Berkers G; Chu MLJN; Arp K; Ghijsen S; Heijerman HGM; Arets HGM; Majoor CJ; Janssens HM; van der Meer R; Bogaert D; van der Ent CK
    J Pers Med; 2021 Apr; 11(5):. PubMed ID: 33925519
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Intestinal Inflammation in Children with Cystic Fibrosis Is Associated with Crohn's-Like Microbiota Disturbances.
    Enaud R; Hooks KB; Barre A; Barnetche T; Hubert C; Massot M; Bazin T; Clouzeau H; Bui S; Fayon M; Berger P; Lehours P; Bébéar C; Nikolski M; Lamireau T; Delhaes L; Schaeverbeke T
    J Clin Med; 2019 May; 8(5):. PubMed ID: 31083321
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Associations between micronutrient intakes and gut microbiota in a group of adults with cystic fibrosis.
    Li L; Krause L; Somerset S
    Clin Nutr; 2017 Aug; 36(4):1097-1104. PubMed ID: 27595636
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Statistical Evaluation of Metaproteomics and 16S rRNA Amplicon Sequencing Techniques for Study of Gut Microbiota Establishment in Infants with Cystic Fibrosis.
    Saralegui C; García-Durán C; Romeu E; Hernáez-Sánchez ML; Maruri A; Bastón-Paz N; Lamas A; Vicente S; Pérez-Ruiz E; Delgado I; Luna-Paredes C; Caballero JD; Zamora J; Monteoliva L; Gil C; Del Campo R
    Microbiol Spectr; 2022 Dec; 10(6):e0146622. PubMed ID: 36255300
    [TBL] [Abstract][Full Text] [Related]  

  • 30. The gut-lung axis in the CFTR modulator era.
    Lussac-Sorton F; Charpentier É; Imbert S; Lefranc M; Bui S; Fayon M; Berger P; Enaud R; Delhaes L
    Front Cell Infect Microbiol; 2023; 13():1271117. PubMed ID: 37780857
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Genetic analysis of Rwandan patients with cystic fibrosis-like symptoms: identification of novel cystic fibrosis transmembrane conductance regulator and epithelial sodium channel gene variants.
    Mutesa L; Azad AK; Verhaeghe C; Segers K; Vanbellinghen JF; Ngendahayo L; Rusingiza EK; Mutwa PR; Rulisa S; Koulischer L; Cassiman JJ; Cuppens H; Bours V
    Chest; 2009 May; 135(5):1233-1242. PubMed ID: 19017867
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Changes in Airway Microbiome and Inflammation with Ivacaftor Treatment in Patients with Cystic Fibrosis and the G551D Mutation.
    Harris JK; Wagner BD; Zemanick ET; Robertson CE; Stevens MJ; Heltshe SL; Rowe SM; Sagel SD
    Ann Am Thorac Soc; 2020 Feb; 17(2):212-220. PubMed ID: 31604026
    [No Abstract]   [Full Text] [Related]  

  • 33. Heterogeneous spectrum of CFTR gene mutations in Korean patients with cystic fibrosis.
    Jung H; Ki CS; Koh WJ; Ahn KM; Lee SI; Kim JH; Ko JS; Seo JK; Cha SI; Lee ES; Kim JW
    Korean J Lab Med; 2011 Jul; 31(3):219-24. PubMed ID: 21779199
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Personalized medicine in CF: from modulator development to therapy for cystic fibrosis patients with rare CFTR mutations.
    Harutyunyan M; Huang Y; Mun KS; Yang F; Arora K; Naren AP
    Am J Physiol Lung Cell Mol Physiol; 2018 Apr; 314(4):L529-L543. PubMed ID: 29351449
    [TBL] [Abstract][Full Text] [Related]  

  • 35. A prospective study to assess the impact of a novel CFTR therapy combination on body composition in patients with cystic fibrosis with F508del mutation.
    Knott-Torcal C; Sebastián-Valles F; Girón Moreno RM; Martín-Adán JC; Jiménez-Díaz J; Marazuela M; Sánchez de la Blanca N; Fernández-Contreras R; Arranz-Martín A
    Clin Nutr; 2023 Dec; 42(12):2468-2474. PubMed ID: 38411018
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Spectrum of CFTR mutations in Chechen cystic fibrosis patients: high frequency of c.1545_1546delTA (p.Tyr515X; 1677delTA) and c.274G>A (p.Glu92Lys, E92K) mutations in North Caucasus.
    Petrova NV; Kashirskaya NY; Saydaeva DK; Polyakov AV; Adyan TA; Simonova OI; Gorinova YV; Kondratyeva EI; Sherman VD; Novoselova OG; Vasilyeva TA; Marakhonov AV; Macek M; Ginter EK; Zinchenko RA
    BMC Med Genet; 2019 Mar; 20(1):44. PubMed ID: 30898088
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Rate of Lung Function Decline in People with Cystic Fibrosis Having a Residual Function Gene Mutation.
    Sawicki GS; Konstan MW; McKone EF; Moss RB; Lubarsky B; Suthoff E; Millar SJ; Pasta DJ; Mayer-Hamblett N; Goss CH; Morgan WJ; Duncan ME; Yang Y
    Pulm Ther; 2022 Dec; 8(4):385-395. PubMed ID: 36319933
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Extended-culture and culture-independent molecular analysis of the airway microbiota in cystic fibrosis following CFTR modulation with ivacaftor.
    Einarsson GG; Ronan NJ; Mooney D; McGettigan C; Mullane D; NiChroinin M; Shanahan F; Murphy DM; McCarthy M; McCarthy Y; Eustace JA; Gilpin DF; Elborn JS; Plant BJ; Tunney MM
    J Cyst Fibros; 2021 Sep; 20(5):747-753. PubMed ID: 33549519
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Ataluren and similar compounds (specific therapies for premature termination codon class I mutations) for cystic fibrosis.
    Aslam AA; Sinha IP; Southern KW
    Cochrane Database Syst Rev; 2023 Mar; 3(3):CD012040. PubMed ID: 36866921
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Impact of Altered Gut Microbiota and Its Metabolites in Cystic Fibrosis.
    Thavamani A; Salem I; Sferra TJ; Sankararaman S
    Metabolites; 2021 Feb; 11(2):. PubMed ID: 33671639
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.